UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
12b-25
Commission
File Number: 001-39555
NOTIFICATION
OF LATE FILING
| ☒ Form 10-K |
☐
Form 20-F |
☐ Form
11-K |
☐ Form
10-Q |
| ☐ Form
10-D |
☐ Form
N-SAR |
☐ Form
N-CSR |
|
For
Period Ended: December 31, 2025
| ☐
Transition Report on Form 10-K |
☐ Transition
Report on Form 10-Q |
| ☐ Transition
Report on Form 20-F |
☐ Transition
Report on Form N-SAR |
| ☐ Transition
Report on Form 11-K |
|
For
the Transition Period Ended: _______________________________________
Nothing
in this form shall be construed to imply that the Commission has verified any information contained herein.
If
the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: _______________________________________
PART
I
REGISTRANT
INFORMATION
| Full name of registrant |
Greenwich LifeSciences, Inc. |
| Former name if applicable |
|
| Address of principal executive office |
3992 Bluebonnet Dr, Building 14 |
| City, state and zip code |
Stafford, TX 77477 |
PART
II
RULE
12b-25 (b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25
(b), the following should be completed. (Check box if appropriate.)
| |
(a) |
The
reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
| ☒ |
(b) |
The
subject annual report, semi-annual report, transition report on Form 10-K, 20-F, 11-K or Form N-SAR or Form N-CSR, or portion thereof
will be filed on or before the 15th calendar day following the prescribed due date or the subject quarterly report or
transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth
calendar day following the prescribed due date; and |
| |
(c) |
The accountant’s
statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART
III
NARRATIVE
State
below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, N-SAR, N-CSR, or the transition report portion thereof, could
not be filed within the prescribed time period.
Greenwich
LifeSciences, Inc. (the “Company”) is unable to file its Annual Report on Form 10-K for the fiscal year ended December 31,
2025 (the “Annual Report”) within the prescribed time period without unreasonable effort and expense. The Company currently
expects to file the Annual Report by April 15, 2025, within the extension period of fifteen calendar days permitted under Rule 12b-25
of the Securities Exchange Act of 1934, as amended.
PART
IV
OTHER
INFORMATION
(1)
Name and telephone number of person to contact in regard to this notification
| Snehal
Patel |
|
(832) |
|
819-3232 |
| (Name) |
|
(Area Code) |
|
(Telephone Number) |
(2)
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s)
been filed? If the answer is no, identify report(s).
☒ Yes
☐ No
(3)
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or portion thereof?
☒ Yes
☐ No
If
so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why
a reasonable estimate of the results cannot be made.
Research and development expenses are anticipated
to have increased by approximately $4.6 million, or approximately 35%, to approximately $17.5 million for the year ended December 31,
2025 from approximately $12.9 million for the year ended December 31, 2024. The increase was primarily the result of increases in clinical
expenses for the Phase III clinical trial.
The amounts reported above are still under review and may differ once
reported in the December 31, 2025 Form 10-K.
Greenwich
LifeSciences, Inc.
(Name
of Registrant as Specified in Charter)
Has
caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.
| Dated: March 31, 2026 |
|
/s/
Snehal Patel |
| |
By: |
Snehal Patel |
| |
Title: |
Chief Executive Officer |
